Mira Pharmaceuticals Announces Selection Of Neuropathic Pain As Indication For Ketamir-2 And Submits Pre-IND Meeting Request To FDA
Mira Pharmaceuticals Announces Selection Of Neuropathic Pain As Indication For Ketamir-2 And Submits Pre-IND Meeting Request To FDA
米拉制药宣布神经病性疼痛被选为Ketamir-2的适应症，并向FDA提交了预IND会议请求。
Mira Pharmaceuticals, Inc. (NASDAQ:MIRA) today announced that it has selected neuropathic pain as the primary indication for its novel oral ketamine analog, Ketamir-2. The Company has submitted a pre-Investigational New Drug (pre-IND) meeting request to the U.S. Food and Drug Administration (FDA) and anticipates the meeting to occur in October 2024. This selection marks a significant milestone as Mira Pharmaceuticals advances toward its IND submission, with plans to begin human trials in the first quarter of 2025.
米拉制药公司（纳斯达克股票代码：MIRA）今天宣布，它已选择神经性疼痛作为其新型口服氯胺酮类似物Ketamir-2的主要适应症。该公司已向美国食品药品监督管理局（FDA）提交了研究前新药（Pre-IND）会议请求，预计会议将于2024年10月举行。这一选择标志着Mira Pharmaceuticals在提交IND方面取得进展的一个重要里程碑，并计划于2025年第一季度开始人体试验。
资讯热榜
更新时间